COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

Clinical Trials and Studies In Down Syndrome

3 Star

A Clinical Trial to test an investigational anti-amyloid vaccine for treatment of Alzheimer's Disease in people with Down Syndrome




It is well known that individuals with Down Syndrome (DS) develop Alzheimer's at a much higher rate than the general population. This research study will test whether an investigational vaccine can affect Alzheimer's-related brain changes in DS. Our clinical research site is looking for individuals who meet the following criteria.

  • Have Down Syndrome
  • Are 25 to 45 years of age
  • Do not have any other serious illness
  • Have a caregiver/informant who can answer questions about you

The study is a randomized, placebo-controlled, double-blinded study. This means that study participants will be randomly given either the active investigational vaccine or a non-active placebo that looks like the active drug; neither the participant nor the study personnel at the clinic will know who is receiving which one.

The study will last 24 months, during which study participants will visit the study clinic 22 times. At each visit, participants will be asked how they are feeling, and at some of the visits they will undergo medical exams, memory tests, blood tests, lumbar punctures (optional), ECG and brain imaging scans. The investigational vaccine and research visit procedures are free of charge. Travel costs will be paid.

For more information or to learn how to participate, please contact:

UCSD: Adult Down Syndrome Program
University of California, San Diego
East Campus office Building (ECOB)
9444 Medical Center Drive
La Jolla, CA, 92037

Phone: 858-249-2526
Fax: 858-249-2535
Ask to speak with Asmaa or Mollie!

group at clinic
See our new video about our research studies and clinical trials.

Contact us

For information about enrolling in a study, please contact:

Adult Down Syndrome Program

See a news article about the biomarkers initiative.